Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia | Topic: Acute Myeloid Leukemia
Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients With mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS) | Topic: Acute Myeloid Leukemia
Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax | Topic: Acute Myeloid Leukemia
QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)–Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction (IND) and Consolidation (CONS) Is Associated With Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts) | Topic: Acute Myeloid Leukemia
QuANTUM-First: Safety by Treatment (Tx) Phase and by Age in Newly Diagnosed (nd) Patients (pts) With FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) | Topic: Acute Myeloid Leukemia
Association Between Transfusion Independence and Survival in Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results From a Large US Health Insurance Claims Database | Topic: Myelodysplastic Syndrome
Patient-Reported Outcomes (PROs) Among Heavily Pretreated Patients (Pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (TB) Treated With Imetelstat in IMerge | Topic: Myelodysplastic Syndrome
Real-World Outcomes of Patients Receiving Oral Specialty Therapy for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia at an Integrated Health System in the United States | Topic: Chronic Lymphocytic Leukemia
Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients With CLL/SLL in US Community Oncology Practices | Topic: Chronic Lymphocytic Leukemia
Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL): A Matching-Adjusted Indirect Comparison (MAIC) | Topic: Chronic Lymphocytic Leukemia
Recent Patterns of Care With BTK Inhibitors and Distribution of Social Determinants of Health Among Patients With CLL/SLL in the US Community Setting | Topic: Chronic Lymphocytic Leukemia
Initial findings from a first-in-human Phase 1a/b trial of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies | Topic: Chronic Lymphocytic Leukemia
Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients | Topic: Chronic Myeloid Leukemia
Ponatinib (PON) vs Asciminib (ASC) as Post-Second Generation (2G) Tyrosine Kinase Inhibitor (TKI) Therapy for Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A Matching Adjusted Indirect Comparison (MAIC) | Topic: Chronic Myeloid Leukemia
Real-World Switching Pattern, Persistence, and Associated Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States | Topic: Non-Hodgkin Lymphoma
Real-World Patterns of Care and Financial Burden Among Patients With Follicular Lymphoma in the US | Topic: Non-Hodgkin Lymphoma
A first-in-human Phase 1 trial of NX-2127, a first-in-class Bruton's Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with relapsed/refractory B-cell malignancies | Topic: Non-Hodgkin Lymphoma
Epcoritamab + GemOx in Patients With R/R DLBCL Ineligible for ASCT: EPCORE NHL-2 Updated Results | Topic: Non-Hodgkin Lymphoma
Single-Agent Epcoritamab Leads to Deep, Durable Responses in R/R FL: Pivotal Data From EPCORE NHL-1 | Topic: Non-Hodgkin Lymphoma
Epcoritamab + R-Mini-CHOP Induces High Complete Metabolic Response (CMR) Rates in Patients With Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Full-Dose R-CHOP: EPCORE NHL 2 Arm 8 Results | Topic: Non-Hodgkin Lymphoma
Subcutaneous Epcoritamab Plus Lenalidomide (E-Len) in Patients (Pts) With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) from EPCORE NHL-5 | Topic: Non-Hodgkin Lymphoma
Prevalence and Economic Burden of Dysphagia in Patients With Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) | Topic: Non-Hodgkin Lymphoma
Efficacy and Safety Is Maintained in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for Up to 3 Years | Topic: PNH
Human Factors Validation Study for a Wearable, Single-Use Injector | Topic: Other blood cell disorders, including idiopathic thrombocytopenic purpura